Methods for determining viral sensitivity to viral inhibitors
AssigneeLaboratory Corporation of America Holdings
InventorJacqueline Denise Reeves
Life of this patent
Estimating the term…
Abstract
Methods and compositions for the efficient and accurate determination of susceptibility of a hepatitis C virus (HCV) or HCV population to an HCV inhibitor. The inhibitor may include, for example, an interferon (IFN), ribavirin (RBV), one or more nucleos(t)ide inhibitors, including for example nucleoside inhibitor-1 (NI-1), 2′C-methyl adenosine (2′CMeA), sofosbuvir (SOF), or non-nucleoside inhibitor targeting site A or B (NNI-A or NNI-B) are provided. The methods may involve determining the genotype of the HCV or the phenotype of the HCV with respect to the inhibitor susceptibility. The methods may further include the selection of a suitable treatment based on the genotype or phenotype determined.
Claims16
A method for selecting a treatment for a patient having a hepatitis C virus (HCV) infection, comprising:
- (a) obtaining a biological sample from the patient, wherein the biological sample comprises an HCV or HCV population from the patient;
- (b) determining the genotype of the HCV or HCV population;
- and
- (c) treating the patient with ribavirin or a nucleoside inhibitor if the HCV or HCV population comprises a genotype 2 (GT2) HCV, genotype 3 (GT3) HCV, genotype 4 (GT4) HCV, or a combination thereof.
A method for determining the susceptibility of a hepatitis C virus (HCV) or HCV virus population to an HCV inhibitor, wherein the HCV inhibitor is ribavirin (RBV) or a nucleoside inhibitor, comprising:
- (a) determining the genotype of the HCV or HCV population;
- and
- (b) determining that the HCV or HCV population is likely to have increased susceptibility to ribavirin or the nucleoside inhibitor as compared to a reference virus if the HCV or HCV population comprises a genotype 2 (GT2) HCV, genotype 3 (GT3) HCV, genotype 4 (GT4) HCV, or a combination thereof.
A method for determining the susceptibility of a hepatitis C virus (HCV) population to an HCV inhibitor, wherein the HCV inhibitor is ribavirin (RBV) or a nucleoside inhibitor (NI), comprising:
- (a) introducing into a cell a resistance test vector comprising a patient derived segment from the HCV viral population, wherein the cell or the resistance test vector comprises an indicator nucleic acid that produces a detectable signal that is dependent on the HCV;
- (b) measuring the expression of the indicator gene in the cell in the absence or presence of increasing concentrations of the HCV inhibitor;
- (c) developing a standard curve of drug susceptibility for the HCV inhibitor, wherein the IC50 fold change value, IC95 fold change value, both, or the slope are detected in the standard curve;
- (d) comparing the IC50 fold change value, IC95 fold change value, or both of the HCV population to IC50 fold change value, IC95 fold change value, or both for a control HCV population or comparing the slope of the standard curve of the HCV population to the slope of the standard curve for a control HCV population;
- and
- (e) determining that the HCV population comprises HCV particles with an increased susceptibility to the HCV inhibitor when the IC50 fold change value, IC95 fold change value, or both are greater for the HCV population as compared to the IC50 fold change value, IC95 fold change value, or both for the control HCV population or determining that the HCV population comprises HCV particles with a reduced susceptibility to the HCV inhibitor when the slope of the standard curve of the HCV population is decreased as compared to the standard curve of the control population.
Dependencies are inferred from the claim text.